- Previous Close
2.1600 - Open
2.0700 - Bid --
- Ask --
- Day's Range
2.0700 - 2.2599 - 52 Week Range
2.0500 - 4.2000 - Volume
16,127 - Avg. Volume
36,193 - Market Cap (intraday)
17.844M - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4000 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is in Phase 2 clinical studies for the treatment of solid tumor, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme, in combination with a range of anti-cancer regimens. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
www.lisata.comRecent News: LSTA
View MorePerformance Overview: LSTA
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LSTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LSTA
View MoreValuation Measures
Market Cap
17.84M
Enterprise Value
-13.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.24
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.23%
Return on Equity (ttm)
-51.77%
Revenue (ttm)
1M
Net Income Avi to Common (ttm)
-19.98M
Diluted EPS (ttm)
-2.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
31.25M
Total Debt/Equity (mrq)
0.47%
Levered Free Cash Flow (ttm)
-13.07M